HDAC9 and lung carcinoma: Although phase III randomized studies do not support the use of HDAC inhibitors in lung cancer patients in routine practice, numerous preclinical studies have shown that HDAC inhibitors exhibit impressive antitumor activity in lung cancer cell lines [43].